ArticlePharmaceutical research2009
Maurocalcine as a non toxic drug carrier overcomes doxorubicin resistance in the cancer cell line MDA-MB 231.
Article in Pharmaceutical research, 2009. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 27 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
27 citing papers in PubMed.
- Scorpion Venom as a Source of Cancer Drugs: A Comprehensive Proteomic Analysis and Therapeutic Potential.International journal of molecular sciences · 2025Review
- Ion-Channel-Targeting Scorpion Recombinant Toxin as Novel Therapeutic Agent for Breast Cancer.Toxins · 2025Article
- Exploring the Chemical Features and Biomedical Relevance of Cell-Penetrating Peptides.International journal of molecular sciences · 2024Review
- A Conjugate between Lqh-8/6, a Natural Peptide Analogue of Chlorotoxin, and Doxorubicin Efficiently Induces Glioma Cell Death.Biomedicines · 2022Article
- [(WR)Cells · 2022Article
- Cell-penetrating peptides improve pharmacokinetics and pharmacodynamics of anticancer drugs.Tissue barriers · 2022Review
- Review
- Single Protein Encapsulated Doxorubicin as an Efficacious Anticancer Therapeutic.Advanced therapeutics · 2020Article
- Early differentiating between the chemotherapy responders and nonresponders: preliminary results with ultrasonic spectrum analysis of the RF time series in preclinical breast cancer models.Cancer imaging : the official publication of the International Cancer Imaging Society · 2019Article
- Polymer-Temozolomide Conjugates as Therapeutics for Treating Glioblastoma.Molecular pharmaceutics · 2018Article
- CPP-Ts: a new intracellular calcium channel modulator and a promising tool for drug delivery in cancer cells.Scientific reports · 2018Article
- In cellulo phosphorylation induces pharmacological reprogramming of maurocalcin, a cell-penetrating venom peptide.Proceedings of the National Academy of Sciences of the United States of America · 2016Article
- Low-dose chemotherapeutic drugs induce reactive oxygen species and initiate apoptosis-mediated genomic instability.Toxicology research · 2016Article
- Biodistribution, Stability, and Blood Distribution of the Cell Penetrating Peptide Maurocalcine in Mice.International journal of molecular sciences · 2015Article
- Article
- Scorpion venom components as potential candidates for drug development.Toxicon : official journal of the International Society on Toxinology · 2015Review
- Enhanced cellular entry and efficacy of tat conjugates by rational design of the auxiliary segment.Molecular pharmaceutics · 2014Article
- Cell motility and drug gradients in the emergence of resistance to chemotherapy.Proceedings of the National Academy of Sciences of the United States of America · 2013Article
- Conjugates of cytochromeExperimental and therapeutic medicine · 2013Article
- Anthracycline Nano-Delivery Systems to Overcome Multiple Drug Resistance: A Comprehensive Review.Nano today · 2013Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeThe aim of this study is to overcome tumour cell resistance that generally develops after administration of commonly used anti-cancer drugs, such as doxorubicin.
methodsRecently, cell penetrating peptides have been used for their ability to deliver non-permeant compounds into cells. One such cell penetrating peptide, maurocalcine, has been isolated from the venom of a Tunisian scorpion. Herein, we report the effects of doxorubicin covalently coupled to an analogue of maurocalcine on drug-sensitive or drug-resistant cell lines MCF7 and MDA-MB 231.
resultsWe demonstrated the in vitro anti-tumoral efficacy of the doxorubicin maurocalcine conjugate. On a doxorubicin-sensitive cancer cell line, the maurocalcine-conjugated form appears slightly less efficient than doxorubicin itself. On the contrary, on a doxorubicin-resistant cancer cell line, doxorubicin coupling allows to overcome the drug resistance. This strategy can be generalized to other cell penetrating peptides since Tat and penetratin show similar effects.
conclusionWe conclude that coupling anti-tumoral drugs to cell penetrating peptides represent a valuable strategy to overcome drug resistance.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.